Literature DB >> 25114033

Editorial commentary: protease inhibitor monotherapy: safe for the CNS in durably suppressed patients?

Scott L Letendre1.   

Abstract

Entities:  

Keywords:  CNS; HIV; antiretroviral; dementia

Mesh：

Substances：

Year:  2014        PMID： 25114033      PMCID： PMC4650774          DOI： 10.1093/cid/ciu645

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  10 in total

1.  Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir.

Authors:  Christine Gutmann; Alexia Cusini; Huldrych F Günthard; Christoph Fux; Bernard Hirschel; Laurent-Arthur Decosterd; Matthias Cavassini; Sabine Yerly; Pietro L Vernazza
Journal:  AIDS       Date:  2010-09-24       Impact factor: 4.177

2.  Updated research nosology for HIV-associated neurocognitive disorders.

Authors:  A Antinori; G Arendt; J T Becker; B J Brew; D A Byrd; M Cherner; D B Clifford; P Cinque; L G Epstein; K Goodkin; M Gisslen; I Grant; R K Heaton; J Joseph; K Marder; C M Marra; J C McArthur; M Nunn; R W Price; L Pulliam; K R Robertson; N Sacktor; V Valcour; V E Wojna
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

3.  Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder.

Authors:  Ronald J Ellis; Scott Letendre; Florin Vaida; Richard Haubrich; Robert K Heaton; Ned Sacktor; David B Clifford; Brookie M Best; Susanne May; Anya Umlauf; Mariana Cherner; Chelsea Sanders; Craig Ballard; David M Simpson; Cheryl Jay; J Allen McCutchan
Journal:  Clin Infect Dis       Date:  2013-12-18       Impact factor: 9.079

4.  HIV-associated neurocognitive disorders: antiretroviral regimen, central nervous system penetration effectiveness, and cognitive outcomes.

Authors:  H M Cross; M I Combrinck; J A Joska
Journal:  S Afr Med J       Date:  2013-09-18

5.  Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia.

Authors:  Nicoletta Ciccarelli; Massimiliano Fabbiani; Manuela Colafigli; Enrico Maria Trecarichi; Maria Caterina Silveri; Roberto Cauda; Rita Murri; Andrea De Luca; Simona Di Giambenedetto
Journal:  Antivir Ther       Date:  2013-03-13

6.  Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?

Authors:  Matteo Vassallo; Jacques Durant; Virginie Biscay; Christine Lebrun-Frenay; Brigitte Dunais; Muriel Laffon; Alexandra Harvey-Langton; Jacqueline Cottalorda; Michel Ticchioni; Helene Carsenti; Christian Pradier; Pierre Dellamonica
Journal:  AIDS       Date:  2014-02-20       Impact factor: 4.177

7.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01

8.  The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial.

Authors:  Pietro Vernazza; Synøve Daneel; Véronique Schiffer; Laurent Decosterd; Walter Fierz; Thomas Klimkait; Matthias Hoffmann; Bernard Hirschel
Journal:  AIDS       Date:  2007-06-19       Impact factor: 4.177

9.  Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy.

Authors:  Magnus Gisslén; Dietmar Fuchs; Lars Hagberg; Bo Svennerholm; Henrik Zetterberg
Journal:  Scand J Infect Dis       Date:  2012-07-09

Review 10.  Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research.

Authors:  Lucette A Cysique; Edward K Waters; Bruce J Brew
Journal:  BMC Neurol       Date:  2011-11-22       Impact factor: 2.474
  10 in total
  1 in total

Review 1.  The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review.

Authors:  Thomas M Gates; Lucette A Cysique
Journal:  CNS Drugs       Date:  2016-01       Impact factor: 5.749
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.